A role for interleukins in ochronosis in a chondrocyte in vitro model of alkaptonuria by Mistry, Jemma et al.
  












Lancaster Medical School, Faculty of Health & Medicine, Lancaster University, LA1 4YB 
2




Dr Adam Taylor 
Lancaster Medical School 




E: a.m.taylor@lancs.ac.uk  






The authors would like to thank the AKU Society, the Rosetrees Trust and University 




Alkaptonuria is a rare autosomal recessive condition resulting from inability to breakdown 
homogentisic acid (HGA); an intermediate in tyrosine degradation. The condition has a triad 
of clinical features, the most damaging of which is ochronotic osteoarthropathy. HGA is 
elevated from birth but pigmentation takes many years. We hypothesise that interleukins play 
a role in initiation and progression of ochronotic osteoarthropathy. 
Methods  
C20/A4 cells were cultured and maintained in 9cm petri dishes containing either HGA at 
0.33mM, a single interleukin (IL-1β, IL-6 or IL-10) at 1ng/ml or a combination of HGA and 
a single interleukin. Statistical analysis of pigment deposits and cell viability was performed 
using analysis of variance with Newman-Keuls post-test. 
Results 
All cultures containing HGA showed a significant increase in pigment deposition compared 
to control and IL cultures alone. The cultures containing HGA and IL-6 showed a significant 
increase in pigment deposits compared to HGA alone.  The cell viability counts across all 
cultures on day 10 demonstrated a significant decrease in cultures containing HGA compared 
to those which did not. There was no significant difference between cultures containing just 
HGA or those combined with an interleukin.   
Conclusions 
This work demonstrates a role for cytokines present in the joint(s) in the pigmentation 
process, particularly IL-6 and that the presence of HGA in joint tissues appears more 
detrimental to chondrocytes than the presence of any of the interleukins found in response to 
joint injury, trauma and OA. This further supports the evidence that the arthropathy in 
alkaptonuria is much more severe and rapidly progressing. 
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Introduction 
Alkaptonuria (AKU) is a rare genetic disorder of autosomal recessive inheritance. It results 
from the absence of homogentisate 1, 2 dioxygenase (HGD), the enzyme responsible for the 
breakdown of homogentisic acid (HGA); an intermediate in the tyrosine degradation 
pathway which is produced primarily by hepatocytes in the liver [1-3]. 
Absence of this enzyme results in a triad of clinical features. Firstly elevated levels of HGA 
is excreted in the urine from birth. This has been observed as early as 57 hours after birth [4] 
and persists throughout life. Overtime elevated levels of HGA in plasma results in an 
increase in the levels of HGA in most tissues, particularly collagenous tissues [5-7]. This 
presence of HGA in collagenous tissues causes the second clinical feature which is 
ochronosis. Ochronosis is the darkening, by polymerisation of the HGA in collagenous 
tissues to give a blue/dark ochre colour to tissues [8]. This second feature is usually evidence 
in the 3
rd
 decade of life and beyond [4]. The final symptom is a result of ochronosis within 
articular cartilages of weight bearing joints giving ochronotic osteoarthropathy. The 
presentation of ochronotic osteoarthropathy is described as mimicking osteoarthritis, but 
being rapidly progressing and earlier in onset [8, 9]. Individuals with AKU have no reported 
shortening of life, but they have a severely affected quality of life with multiple joint 
replacements, cardiac co-morbidities and calculi in numerous tissues [6, 10-14]. 
There has been advances in understanding the end stage manifestations of AKU and its use 
as a model for documenting new advances in understanding “common” OA and other 
arthropathies is shedding new light on disease processes [8, 9, 15]. There also appears to be a 
potential therapy for AKU. Many potential therapies have been suggested [4, 16] but most 
have side effects. There is growing interest in Nitisinone, a triketone herbicide used 
primarily to treat Hereditary Tyrosinaemia type I [17,18], but also with a huge potential in 
AKU [19,20]. Early work has shown its effectiveness at reducing urinary HGA [20-22]. 
Whilst there is promise in the therapy to prevent ochronosis there is still a gap in the 
understanding of ochronosis. It is clear that pH has an effect on the conversion of HGA to 
polymer [23], as urine goes dark from birth [4]. However the ochronosis, following 
conversion of HGA to polymer that occurs in tissues, particularly joint cartilages takes a 
number of years to occur [24]. This delay in pigmentation from ochronosis within joints 
  
suggests that there is protection within the collagenous tissues or a factor that is intrinsic to 
the joint in later life plays a role in the pigmentation process.  
One factor that has been shown to be increased as far as ochronosis is concerned is the 
oxidative stress encountered by cells in AKU patient tissues [25-28]. However, the presence 
of HGA alone cannot be the sole factor in causing the pigmentation given HGA is present 
systemically, if not from birth, hours or days shortly after for many years prior to joint 
manifestations caused by ochronosis. There must be some other factor that causes the onset 
of pigmentation in these tissues.  
There is still much to discover about the pathogenesis of AKU, and similarly OA. The 
majority of research focuses on the role of cartilage and chondrocytes in the initiation and 
development of the conditions. In OA, research has highlighted that the loss of 
proteoglycans and cleavage of type II collagen occurs on the surface of cartilage [29]. This 
makes the cartilage permeable by increasing water content, which in turn decreases the 
tensile strength of cartilage making it susceptible to erosion and degradation. However, in 
early OA, the chondrocytes have been found to exhibit a transient proliferative response, and 
increase the synthesis of cartilage matrix, as an early repair mechanism [30, 31]. In AKU, an 
alteration in the cartilage matrix strength and composition is also seen at end stage [8,9], but 
what drives this is unclear. 
What is clear is that development of OA and potentially AKU stems from the chondrocytes 
and their failure to maintain a balance between synthesis and degradation of extracellular 
matrix [32-36]. On examination of ochronotic surgical waste tissues the pigmentation is not 
uniform [8]. If HGA was the sole factor for pigmentation, given its systemic presence all 
joint tissues should be equally pigmented. In light of the patchy, non-uniform pigmentation a 
potential focussed local factor within certain areas of tissues may be responsible for 
initiating the pigmentation process. Local trauma in joints, either due to over exertion or 
trauma/damage may sufficiently disturb the equilibrium that (just about) existed prior to 
injury. 
Chondrocytes respond to biochemical and biomechanical stimuli and in doing so produce 
anabolic factors and catabolic factors which can promote extracellular matrix formation or 
degradation, respectively. The mechanical and biological stresses within the joint stimulate 
the production of inflammatory cytokines. There is evidence that the chondrocytes are a 
source of production of cytokines, in particular interleukin 1 (IL-1β) which in turn induces 
  
the expression of MMPs, which contribute to ECM degradation [37]. It is IL-1β and tumour 
necrosis factor (TNF-α) that are heavily implicated in the initiation and progression of OA. 
They have a synergistic relationship and increase the production of prostaglandin E2 (PGE2) 
stimulating the activities of other inflammatory pathways.  
Within a normal joint, cytokines and growth factors are produced in small quantities and 
released into synovial fluid to act on resident cells. In OA, and potentially AKU, this fine 
homeostatic balance is disturbed. Cytokines are categorised into 4 groups based on function; 
catabolic, regulatory, inhibitory and anabolic. IL-1β and TNF-α are known to be potent pro-
inflammatory cytokines. They are produced in response to cell stress. In OA it is TNF-α that 
drives inflammation, but IL-1β that sustains it and promotes cartilage erosion, whilst also 
stimulating the induction of PGE2 by other inflammatory pathways. The chondrocytes 
respond to these pro-inflammatory cytokines by increasing the production of proteinases, 
prostaglandins and nitric oxide [36, 38, 39].  
IL-6 is classed as a pro-inflammatory cytokine. It predominantly modulates the effects of 
catabolic cytokines involved in cartilage destruction, and is often found in the synovial fluid 
of OA joints. It is produced by osteoblast cells in response to stimulation by IL-1β [40, 41]. 
IL-10 is classed as an anti-inflammatory cytokine due to its ability in vitro to decrease the 
production and activity of catabolic cytokines [42]. This cytokine, is also found within the 
synovial fluid of OA joints. Interestingly IL-10 along with IL-4, in vivo, has been found to 
be chondroprotective. Testing in murine models of streptococcal cell wall arthritis, a 
combination of IL-10 and IL-4 was shown to be a potent down-regulator of the natural 
inflammatory response in OA [43]. In this paper we utilise one cytokine from 3 of the 
categories; IL-1β, IL-6 and IL-10, either alone or in combination with HGA to examine the 
effects on cell viability and the pigmentation seen in ochronosis in AKU to highlight 
potential other contributory factors to the pigmentation process.  
Materials and Methods  
All reagents including HGA and Interleukins (IL-1β, IL-6 and IL-10) were obtained from 
Sigma-Aldrich (Dorset, UK) unless otherwise stated. Plasticware was purchased from 
Appleton Woods (UK).  
Cell culture 
  
C20/A4 immortalized chondrocytes were a kind gift from Dr Mary B Goldring (Hospital for 
Special Surgery, NY, USA) [44]. C20/A4 cells were cultured and maintained in 9cm petri 
dishes containing DMEM/Ham’s F12 (1:1). The cells were maintained at 37°C in a 
humidified atmosphere of 5% CO2. Medium was changed every 3 days. Medium was 
supplemented with HGA at concentrations of 0.33mM, as previously described [24]. 
Interleukins were added to relevant wells at 1ng/ml.  
 
Identification and quantitation of ochronotic pigment deposition in vitro in the 
presence and absence of Interleukin’s  
Cells were cultured and seeded as previously described with minor modifications for cell type 
(24). Specifically, C20/A4 cells were cultured in 9cm petri dishes to confluence and then 
trypsinised and counted using a disposable C-Chip hemocytometer (Labtech International, 
UK), and light microscope. They were then seeded at a density of 4 × 104 cells/well into 24-
well plates containing 13-mm diameter sterile glass coverslips. Medium was changed every 
3
rd
 day and the supernatant spun down and stored at -80
o
C. Cells were allowed to grow for 
either 10 or 21-23 days. At these time points coverslips were washed 3 times with PBS 
solution in order to remove residual media and then were fixed using a 10% PBFS solution. 
Coverslips were then stained with Schmorls reagent, rinsed in distilled water, counter stained 
with nuclear fast red, dehydrated in alcohols and mounted on a glass slide using DPX 
microscopy mountant [24].  
Pigmentation, each deposit counted as a blue microscopic deposit within the field of view, 
was quantified by photographing 6 random areas on each slide and overlaying a grid on the 
image and then counting the number of pigment deposits/area and then calculating the 
average [24]. 
 
Influence of HGA on cell growth and viability 
C20/A4 cells were seeded into 24-well plates at a concentration of 4 × 104cells per well and 
grown for up to 10 days in 1 ml of medium supplemented with 0.33mM HGA and 1ng/ml of 
interleukin (either IL-1β, IL-6 or IL-10).  
 
Cell layers were washed, trypsinised and counted in disposable haemocytometers (Labtech 
International, UK). Trypan blue exclusion assay was used to determine viability. 
Statistical analysis 
  
Statistical analysis of pigment deposits (days 10 and 21-23) and cell viability (day 10) was 
performed using analysis of variance on Graphpad Prism 5 software (La Jolla, CA, USA). 
Differences between groups was determined by Newman-Keuls post-test. 
Ethical Approval 
This study was approved by Lancaster University Research Ethics Committee.  
Results 
Cultures of C20/A4 cells with HGA added to them showed the characteristic darkening (data 
not shown), indicative of ochronosis as the result of polymerisation of HGA in both cultures 
with HGA and also those with the combination of HGA & IL’s, there was no obvious 
macroscopic difference in darkening between the two groups. There was also no obvious 
macroscopic difference in the darkened appearance of the media between the interleukin’s 
(IL-1β vs IL-6 vs IL-10) on any given day, although those from day 21-23 were darker than 
those on day 10 (data not shown). 
(Figure 1 here)  
Both control and IL-1β supplemented cultures shown in (Figure 1) appear healthy and viable 
at both time points, as demonstrated by a continuous presence of C20/A4 cells when viewed 
during culture and histological examination. The cultures containing HGA, either alone or in 
combination with IL-1β, contrasted to the controls, showed a decrease in the number of cells 
– but as expected an increased number of blue staining area indicative of pigment deposits. 
The staining indicating pigmentation was visible both intra- and extracellularly in the cultures 
containing HGA.  
No pigment deposition was seen in the control and IL-1β cultures. There were statistically 
significant increases in the amount of pigment deposition in both cultures containing HGA, 
when compared to both control & IL-1β alone. After 10 days in culture there was slightly 
more pigment deposits/unit area than HGA+IL-1β, but this was not a significant increase. 
After 21 days there was more pigment deposits in the cultures containing HGA, but these 
were not significantly different from each other.   
(Figure 2 here) 
The viability of cells cultured with HGA, IL-1β or in combination demonstrated a significant 
decrease when compared to the control group. There was no significant difference between 
  
those containing HGA, both were significantly reduced compared to the control but not 
different to each other. Interestingly, the cultures containing HGA, either alone or in 
combination with IL-1β were significantly reduced compared to the culture containing only 
IL-1β (Figure 2). This is indicative of the effect of HGA being more detrimental to the 
viability of cells than the presence of IL-1β.  
(Figure 3 here) 
The results from cultures containing HGA and IL-6 show that after 10 days the number of 
pigment deposits seen is significantly increased in those containing HGA+IL-6 compared to 
all other. On day 23 the number of pigment deposits per unit area increased compared to day 
10 in both cultures containing HGA. On day 23 there was a significant increase in the number 
of pigment deposits in the HGA culture compared to the control. As with day 10, there was a 
significant increase in the number of pigment deposits per unit area in the culture containing 
HGA+IL-6 compared to HGA alone (Figure 3).  
(Figure 4 here) 
The viability of C20/A4 cells cultured in HGA and or IL-6 showed no significant difference 
between the control cells and those cultured in IL-6. The cultures containing HGA, both 
alone and with IL-6 were significant reduced compared to the control and IL-6 alone. There 
was no significant difference in the number of cells when comparing the cultures containing 
HGA; alone and with IL-6. The presence of HGA either alone, or in combination with IL-6 
appears more detrimental to the cells than IL-6 alone (Figure 4). 
(Figure 5 here) 
The C20/A4 cultures with IL-10 for 10 days showed no significant differences across any of 
the cultures. By day 21 the number of pigment deposits in HGA only culture had increased, 
but those containing HGA+IL-10 had increased only slightly. By day 21 there was a highly 
significant increase in the number of pigment deposits in the HGA culture compared to the 
control and a significant increase in pigment deposits in the HGA+IL-10 compared to the 
control. The comparison of number of pigment deposits between the culture containing HGA 
and HGA+IL-10 showed no significant differences (Figure 5).  
(Figure 6 here) 
The effect of HGA and IL-10 on cell numbers showed that compared to the control IL-10 
showed a small decrease in cell number, but this was not significant. Both cultures which 
  
contained HGA were significantly decreased compared to the control culture and that 
containing IL-10 alone. There was no significant difference between the cultures containing 
HGA and those containing HGA+IL-10. 
 
Discussion 
This manuscript is the first to propose a possible role for another factor; IL-6, in the 
pigmentation process in AKU. HGA in joint tissues of patients with AKU is key, for the 
initiation and progression of the polymerisation process leading to arthritis and joint 
destruction in this condition. It has been demonstrated that HGA is present in AKU patients 
urine from birth [4], but the polymerisation seen in joint tissues does not seem to be 
immediate, as detailed by the years it takes for polymerisation to occur in vivo [24]. It may be 
that other factors, such as IL-6 may have a possible role in the pigmentation process. There is 
limited data or hypotheses in the published literature that elucidates any information on why 
the pigmentation process is not as quick as the dark colouration of urine. Given that 
individuals with AKU are as likely as other individuals without the condition to suffer from 
other age related joint conditions such as OA, the pigmentation process occurring as part of 
ochronotic osteoarthropathy may be marking cells which are damaged or undergoing age 
related changes.  
It is known that IL-1β inhibits chondrocyte proliferation [45] and influences apoptosis in 
chondrocytes [46]. Our results show that the effect of IL-1β on chondrocytes is consistent 
with the published literature, a significant decrease in cell number compared to the control 
cultures. The effect of HGA on cell number is far more detrimental than that observed with 
IL-1β alone. This suggests that the effect HGA has is far more destructive to chondrocytes 
within the cartilage matrix. Interestingly the combination of HGA+IL-1β does not show a 
significant difference when compared to the HGA alone, this combination does show a 
significant decrease in the number of cells when compared to IL-1β alone. Initially, at day 10 
the culture containing HGA alone shows more, although not significant, pigmentation 
compared to HGA+IL-1β. After 21 days the combination culture shows more pigmentation 
than HGA alone. This may mean that longer exposure to IL-1β is needed to exert an effect on 
the pigmentation process. It has been shown that IL-1β is highest initially 24 hours after 
trauma, but can be elevated for weeks or months following the incident [47-52]. When 
considered in combination the results of the cell viability assay and pigmentation suggest that 
  
over time potentially fewer cells are responsible for the pigmentation process that is 
occurring, or the pigmentation that is occurring is not solely cellular in origin. However, the 
evidence suggests cells are key to driving the pigmentation process [24]. 
The pigmentation seen in cultures with HGA and IL-6 show that a combination of both 
shows a significant increase in pigmentation above that seen in HGA alone at both day 10 
and day 23 (P<0.01 on both time points). Similarly the effect of HGA and IL-6 shows a 
significant decrease in cell viability when compared to both the control cultures and IL-6 
alone. Interestingly there was no significant difference seen between the control and the IL-6 
cultures. IL-6 has a role in OA, with a strong correlation between elevated IL-6 and OA [53, 
54]. The effect of HGA on the cultures appears to be greater than that of IL-6 alone, with a 
combination of IL-6 and HGA showing similar viability, not significantly different, to that of 
HGA alone.  
Interestingly, IL-10 with its chondroprotective properties [55, 56], did not seem to reduce the 
effects of HGA. The early (day 10) cultures of HGA+IL-10 show no significant difference 
compared to HGA alone. By day 21, the amount of pigmentation had increased in both 
cultures containing HGA, with the HGA showing a much larger increase compared to 
HGA+IL-10, which increased slightly, the difference between the two was not significant. 
This suggests that any potential protective effect from IL-10 is not seen immediately or in the 
short term (10 days). IL-10 may take longer to exert any chondroprotective effect in the 
presence of HGA and this may be why the 21 day culture of HGA+IL-10 had not increased at 
the same rate as HGA alone, any effect it may have is not significant compared to HGA. The 
presence of IL-10 has no significant effect on the pigmentation rate, mirroring the absence of 
significance between number of viable cells compared between HGA and HGA+IL-10. 
IL-1β appears to have the most significant reduction/effect on cell number compared to 
control. This greater reduction in viable cells compared to IL-6 & IL-10 vs their control, is 
potentially part of the reason why the arthropathy in AKU is faster and of a more rapid onset 
than that seen in the more common OA. The condition is often mis-diagnosed as OA [4, 57, 
58], but little is known about the potential overlap of physiological disease processes. 
Evidence exists in the literature characterising the more severe and rapidly progressing 
anatomicopathological changes in joint tissues of AKU sufferers compared to OA [8].  
The presence of HGA in AKU tissues has been shown to increase oxidative stress on cells 
[25-27,59], this involvement of changes in the antioxidant defences is also seen in OA with 
  
both IL-1β and IL-6 shown to dysregulate antioxidant defences in chondrocytes [60]. The 
significance of the IL-6 results presented in this study, showing a significant increase in 
pigmentation compared to HGA and IL-6 alone presented in this study are supported by 
clinical evidence that there is a significant increase in serum IL-6 in AKU patients compared 
to control [61]. Previous in vitro work has shown that chondrocytes challenged with HGA 
show a significant increase in pro-inflammatory cytokines, with IL-6 being the most 
significantly increased [62]. This study also demonstrated that the AKU patients had higher 
serum levels of C-reactive protein and IL-1β although this was not significant [61].  
Our results further support the theory that regardless of the presence of any of the 
interleukins, their effect seems less detrimental to cultures of chondrocytes compared to that 
of HGA. In the clinical setting this suggests that the most beneficial strategy for patients 
would be to target the reduction or eradication of HGA from tissues and plasma to minimise 
the chance of pigmentation and the effect the HGA has on cells.  
There is currently new hope for sufferers of AKU, with the trial of Nitisinone in patients with 
the condition [19], the elimination of HGA from the body will prevent the pigmentation 
process in individuals. However, there are many sufferers, particularly in the developing 
world who will not have access to this treatment and need to reduce their risk of pigmentation 
at an early age. These patients could benefit from avoiding over exertion and traumatic insult 
on joint tissues and the production of cytokines that have the potential to reduce cell number 
in combination with HGA and increase the rate of pigmentation, leading to joint disease, 
failure and ultimate need for replacement. In individuals that are taking Nitisinone, there is 
the possibility of complications and the therapy may need to be halted or removed 
completely. Some patients report elevated plasma tyrosine levels and corneal opacities [21], 
but on the whole Nitisinone appears relatively well tolerated.  
Our cultures utilised a concentration of HGA that has been tested previously in in vitro 
models of AKU, but more importantly is physiologically within the range seen in plasma of 
patients with AKU [24]. This raises the question of what other potential factors may be acting 
within cartilaginous tissues that are affected by pigmentation in alkaptonuric patients and 
how these may be understood to prevent pigmentation in individuals who do not have access 
to the promising and effective therapeutic agent Nitisinone[19, 63]. Results presented in this 
study show that IL-6 may be partly responsible for an increase in pigmentation compared to 
the HGA alone, but what promotes the presence of IL-6 at an increased level in AKU patients 
  
still needs further investigation [61]. Is it the presence of HGA or its polymeric derivatives 
that increases the oxidative stresses and drives inflammation, or are inflammatory cytokines 
released in response to trauma and this initiates and drives the pigmentation process? 
Key Messages 
HGA is more detrimental to chondrocyte viability than interleukins hence alkaptonuria 
arthropathy is more severe. 
IL-6 appears to be involved in increasing ochronotic pigmentation in alkaptonuria 
IL-1β and IL-10 do not appear to affect ochronotic pigmentation in alkaptonuria. 
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Figure Legends 
Figure 1: Mean number of pigment deposits in 10 day (left) and 21 day (right). C20/A4 cell 
cultures supplemented with HGA and IL-1β. Pigment counts from x10 magnification images, 
expressed as the number of deposits per unit area. Results are the mean of 6 fields from 6 
coverslips. Error bars signify the SEM. Statistically significant differences between groups 
denoted by ** p<0.01 and *** p<0.001. 
Figure 2: Mean number of viable cells in 10 day C20/A4 cell cultures supplemented with 
HGA and IL-1β. Number of viable cells expressed as the number of cells per ml. Results are 
the mean of 5 counts from each of 6 wells. Error bars signify the SEM. Statistically 
significant differences between groups denoted by ***p<0.001. 
Figure 3: Mean number of pigment deposits in 10 day (left),and 23 day (right). C20/A4 cell 
cultures supplemented with HGA and IL-6. Pigment counts from x10 magnification images, 
expressed as the number of deposits per unit area. Results are the mean of 6 fields from 6 
coverslips. Error bars signify the SEM. Statistically significant differences between groups 
denoted by *p<0.05, ** p<0.01 and *** p<0.001. 
Figure 4: Mean number of viable cells in 10 day C20/A4 cell cultures supplemented with 
HGA and IL-6. Number of viable cells expressed as the number of cells per ml. Results are 
the mean of 5 counts from each of 6 wells. Error bars signify the SEM. Statistically 
significant differences between groups denoted by ***p<0.001. 
  
Figure 5: Mean number of pigment deposits in 10 day (left) and 21 day (right). C20/A4 cell 
cultures supplemented with HGA and IL-10. Pigment counts from x10 magnification images, 
expressed as the number of deposits per unit area. Results are the mean of 6 fields from 6 
coverslips. Error bars signify the SEM. Statistically significant differences between groups 
denoted by *p<0.05, ** p<0.01 and *** p<0.001. 
Figure 6: Mean number of viable cells in 10 day C20/A4 cell cultures supplemented with 
HGA and IL-10. Number of viable cells expressed as the number of cells per ml. Results are 
the mean of 5 counts from each of 6 wells. Error bars signify the SEM. Statistically 
significant differences between groups denoted by ***p<0.001. 
 
 
